Organisation paid for research Program year 2025 Source: CMS Open Payments

The Jackson Clinic PA

Neither a doctor nor a teaching hospital

Research payments

$570,672

149 payments

Through program year 2025, The Jackson Clinic PA is reported as receiving $570,672 in research payments, across 149 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $72,914 18
2024 Research $17,116 5
2023 Research $104,275 18
2022 Research $19,749 11
2021 Research $30,459 28
2020 Research $121,474 50
2019 Research $204,685 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sebela Pharmaceuticals Inc. $156,663 25 payments
  2. Pfizer Inc. $124,960 21 payments
  3. Akcea Therapeutics, Inc. $110,687 8 payments
  4. AbbVie, Inc. $88,328 71 payments
  5. Sumitomo Pharma America, Inc. $40,568 12 payments
  6. Amgen Inc. $28,128 2 payments
  7. Ionis Pharmaceuticals, Inc. $18,838 9 payments
  8. Exact Sciences Corporation $2,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $150,163 23 payments
  2. Global Prevalence of Transthyretin Amyloid Cardiomyopathy Attrcm in Participants With Heart Failure With Preserved Ejection Fraction Hfpef $105,315 11 payments
  3. Isis 678354-Cs2 $96,613 7 payments
  4. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $40,568 12 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $28,123 1 payment
  6. M16-283 $27,252 15 payments
  7. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $19,645 10 payments
  8. M14-702 $17,821 16 payments
  9. Is354cs9 $17,638 7 payments
  10. A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $15,729 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record